Home » Stocks » PALI

Palisade Bio, Inc. (PALI)

Stock Price: $2.93 USD -0.23 (-7.28%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $2.89 -0.04 (-1.37%) Jul 30, 7:58 PM
Market Cap 21.39M
Revenue (ttm) 7,500
Net Income (ttm) -10.98M
Shares Out 2.89M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $2.93
Previous Close $3.16
Change ($) -0.23
Change (%) -7.28%
Day's Open 3.02
Day's Range 2.82 - 3.16
Day's Volume 935,985
52-Week Range 2.82 - 16.02

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Statistically significant 1.1-day acceleration in return of bowel function

3 days ago - GlobeNewsWire

Palisade Bio Inc (NASDAQ: PALI) has entered into an exclusive license with the Regents of the University of California, expanding its technology for detecting enzymatic protease activity in human clinic...

2 weeks ago - Benzinga

Former Leading BioSciences Chairman and Retired Board-Certified Surgeon, Dr. David Berry to Serve as Chair Former Leading BioSciences Chairman and Retired Board-Certified Surgeon, Dr. David Berry to Ser...

1 month ago - GlobeNewsWire

The FDA has granted Fast Track Designation to Palisade Bio Inc's (NASDAQ: PALI) investigational drug LB1148, which has the potential to be the first oral treatment to reduce adhesions following abdomina...

2 months ago - Benzinga

LB1148 was previously granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of postoperative GI dysfunction associated with pediatric cardiovascular surgery

2 months ago - GlobeNewsWire

Topline results expected in H1-2021 Topline results expected in H1-2021

2 months ago - GlobeNewsWire

Webinar on Thursday, May 13th @ 1pm ET Webinar on Thursday, May 13th @ 1pm ET

2 months ago - GlobeNewsWire

GERMANTOWN, Md., April 26, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA) ("Seneca" or the "Company"), disclosed on April 23, 2021, the passing of the final proposal required for approval of...

Other stocks mentioned: SNCA
3 months ago - PRNewsWire

Privately-held Leading BioSciences Inc entered into a definitive agreement for a reverse merger with Seneca Biopharma Inc (NASDAQ: SNCA) has announced data from an open-label gastrointestinal (GI) surge...

Other stocks mentioned: SNCA
3 months ago - Benzinga

Video message details merger closing process following completion of the April 23 virtual Special Meeting as well as next planned milestones for the merged company to be renamed Palisade Bio

Other stocks mentioned: SNCA
3 months ago - GlobeNewsWire

GERMANTOWN, Md., April 12, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA) ("Seneca" or the "Company"), announced the preliminary voting results of its Special Meeting of Stockholders on Apri...

Other stocks mentioned: SNCA
3 months ago - PRNewsWire

Video message explains the multiple benefits of the proposed merger and provides an overview of the substantial market opportunity for the combined company to be named Palisade Bio

Other stocks mentioned: SNCA
3 months ago - GlobeNewsWire

Combined company, to be named Palisade Bio, will be well-positioned to leverage its compelling therapeutics pipeline, strong cash position, and accomplished management and Board to maximize stockholder ...

Other stocks mentioned: SNCA
4 months ago - GlobeNewsWire

GERMANTOWN, Md., March 24, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA) (the "Company") today announced that the Company adjourned its special meeting of stockholders scheduled for Wednesd...

Other stocks mentioned: SNCA
4 months ago - PRNewsWire

GERMANTOWN, Md., March 22, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today r...

Other stocks mentioned: SNCA
4 months ago - PRNewsWire

Seneca Biopharma (SNCA) stock is on the rise as investors prepare for an upcoming meeting covering a merger and reverse stock split. The post SNCA Stock: Seneca Biopharma Shares Rocket Ahead of Merger, ...

Other stocks mentioned: HOL, SNCA, SNDL, TWTR, VACQ
4 months ago - InvestorPlace

GERMANTOWN, Md., March 17, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), today announced that leading independent proxy advisory firm Institutional Shareholder Services, Inc. ("ISS") has r...

Other stocks mentioned: SNCA
4 months ago - PRNewsWire

NEW YORK, March 11, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights o...

Other stocks mentioned: CLGX, RNET, SNCA, VGAC
4 months ago - PRNewsWire

GERMANTOWN, Md., Jan. 20, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today an...

Other stocks mentioned: SNCA
6 months ago - PRNewsWire

Regeneron Pharmaceuticals (NASDAQ: REGN) shares are trading higher after the company announced an additional U.S. order to purchase 1.25 million doses of its COVID-19 antibody cocktail bringing the tota...

Other stocks mentioned: JAGX, REGN, SNCA
6 months ago - Benzinga

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Buildingin New York City...

Other stocks mentioned: SNCA
7 months ago - PRNewsWire

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Seneca Biopharma, Inc. (NASDAQ: SNCA) and its board of directors concerning the merger of ...

Other stocks mentioned: SNCA
7 months ago - PRNewsWire

NEW YORK, Dec. 17, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Seneca Biopharma, Inc. ("Seneca" or the...

Other stocks mentioned: SNCA
7 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Seneca Biopharma, Inc. (NASDAQ: SNCA) and Leading BioSciences, Inc. is fair to Sene...

Other stocks mentioned: SNCA
7 months ago - Business Wire

GERMANTOWN, Md., Dec. 15, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today an...

Other stocks mentioned: SNCA
7 months ago - PRNewsWire

GERMANTOWN, Md., Aug. 13, 2020 /PRNewswire/ -- Seneca Biopharma, Inc.

Other stocks mentioned: SNCA
11 months ago - PRNewsWire

GERMANTOWN, Md., May 22, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, reported ...

Other stocks mentioned: SNCA
1 year ago - PRNewsWire

GERMANTOWN, Md., May 22, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq:SNCA), a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet medical need...

Other stocks mentioned: SNCA
1 year ago - PRNewsWire

GERMANTOWN, Md., May 15, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today rep...

Other stocks mentioned: SNCA
1 year ago - PRNewsWire

About PALI

Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery. The compa... [Read more...]

Industry
Biotechnology
Founded
1996
CEO
I. Richard Garr
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
PALI
Full Company Profile

Financial Performance

In 2020, Palisade Bio's revenue was $13,520, a decrease of -12.17% compared to the previous year's $15,394. Losses were -$16.27 million, 94.8% more than in 2019.

Financial Statements